2018.Nov.02
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States
Date of occurrence of the event: Nov 02, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: Phase III clinical study of OBI’s active immunotherapeutic drug Adagloxad Simolenin (OBI-822) is planned to target Triple Negative Breast Cancer (TNBC) subjects […]
This article is password protected.
To view the content, please enter your password in the field below